Assigment .Apa seven . All instructions attached.

Original Research

Scheduled, Simultaneous Dosing of Pregabalin, Celecoxib, and Acetaminophen Markedly Reduces or Eliminates Opioid Use After ACL Reconstruction Using Allograft or Hamstring Tendon Autograft

A Randomized Clinical Trial

Jeffrey D. Swenson,*† MD, Kevin M. Conrad,† MD, Nathan L. Pace,† MD, MStat, Kathleen Phillips,‡ RPh, and Charles L. Saltzman,§ MD

Investigation performed at Orthopedic Center, School of Health Sciences, University of Utah, Salt Lake City, Utah, USA

Background: Opioid analgesics continue to be prescribed after ambulatory surgery despite untoward adverse effects, risk of overdose, and association with substance use disorder.

Purpose/Hypothesis: The purpose was to investigate the use of a novel system to provide scheduled and simultaneous dosing of acetaminophen, celecoxib, and pregabalin after anterior cruciate ligament reconstruction (ACLR). It was hypothesized that this system would markedly reduce pain and opioid use compared with existing best practice.

Study Design: Randomized controlled trial; Level of evidence, 1.

Methods: Included were 100 patients scheduled for elective, primary ACLR using allograft or hamstring tendon autograft. Selection criteria included age between 18 and 65 years and weight between 65 and 120 kg. Exclusion criteria were a known allergy to any drug used in the study or the use of opioid analgesics before surgery. Patients in the intervention group received a blister pack with scheduled, simultaneous doses of acetaminophen, celecoxib, and pregabalin; patients were also given oxyco- done 5 mg as needed for breakthrough pain. Patients in the control group were prescribed ibuprofen and oxycodone 5 mg/ acetaminophen 325 mg as needed for pain. The primary outcome measure was pain. Secondary outcomes were nausea, itching, and daily oxycodone use. Patients were asked to quantify their average pain at rest, nausea, and itching on an 11-point verbal scale (from 0 to 10). These data were recorded for 6 days during daily telephone contacts with patients after hospital discharge.

Results: Cumulative results for 6 days showed significantly lower values in the intervention group compared with the control group for pain (median [interquartile range], 28 [14-35] vs 35 [28-41], respectively; P ¼ .009) and oxycodone use (median [interquartile range] number of tablets, 0 [0-2] vs 8 [1.25-16], respectively; P < .001). Based on these data, the upper tolerance limits for the number of oxycodone tablets required by 90% of patients in the intervention and control groups were 8 tablets and 30 tablets, respectively. Cumulative results for nausea and itching were also significantly lower for the intervention group. Most patients in the intervention group used no opioids during recovery.

Conclusion: Simultaneous dosing of 3 nonopioid analgesics resulted in reduced postoperative pain and markedly lower opioid use.

Registration: NCT04015908 (ClinicalTrials.gov identifier).

Keywords: postoperative pain; opioids; multimodal; analgesia

Opioid analgesics continue to be prescribed after ambulatory surgery despite untoward adverse effects, risk of overdose, and association with substance use disorders.1 Without an effective alternative, providers are understandably

The Orthopaedic Journal of Sports Medicine, 10(12), 23259671221140837 DOI: 10.1177/23259671221140837 ª The Author(s) 2022

1

This open-access article is published and distributed under the Creative Commons Attribution - NonCommercial - No Derivatives License (https://creativecommons.org/ licenses/by-nc-nd/4.0/), which permits the noncommercial use, distribution, and reproduction of the article in any medium, provided the original author and source are credited. You may not alter, transform, or build upon this article without the permission of the Author(s). For article reuse guidelines, please visit SAGE’s website at http://www.sagepub.com/journals-permissions.

reluctant to withhold opioids in the setting of moderate to severe postoperative pain. To this end, a variety of proce- dural and pharmacologic treatments have been used to reduce opioid requirements after hospital discharge.

Many existing protocols for reduced or “opioid-free” recovery simply impede or eliminate access to opioid analgesics.5,12,15,17,23 This practice may reduce opioid use at the expense of inadequately treating pain. Truly effective nonopioid analgesia should decrease opioid use even for patients with unrestricted access to opioids during recovery.

Three classes of nonopioid analgesics are practical for use in an outpatient setting. Acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and gabapentinoids all produce significant reductions in opioid requirements and opioid-related side effects.16,21,24 To date, there are limited data describing the simultaneous effect of all 3 drug classes after hospital discharge.17 Patient compliance with complex drug regimens may limit the use of multimodal analgesia after hospital discharge.22

In this prospective randomized trial, we investigated the use of a novel drug packaging system to facilitate the utili- zation of 3 commonly prescribed nonopioid analgesics after ambulatory orthopaedic surgery (anterior cruciate liga- ment reconstruction [ACLR]). We hypothesized that improved compliance with the scheduled, simultaneous administration of these 3 nonopioid analgesics would mark- edly reduce pain and opioid use after primary ACLR com- pared with existing methods for pain control.

METHODS

This study received institutional review board approval and was registered with ClinicalTrials.gov (NCT04015908). Written informed consent was obtained from all partici- pants. Consecutive eligible patients having elective, iso- lated, and primary ACLR using either semitendinosus autograft or allograft between January 2020 and February 2021 were asked to participate in the study. Enrollment was limited to patients having hamstring autograft or allo- graft in order to minimize variability of surgical stimulus that may be associated with other graft options, such as patellar or quadriceps tendon. Additional criteria for inclu- sion were age between 18 and 65 years and weight between 65 and 120 kg. Patients were excluded if they had a known allergy to any drug used in the study, were using opioid analgesics before surgery, or did not consent for adductor canal block (ACB) for postoperative pain management.

There was no masking of study group assignment for sur- geon, anesthesiologist, research personnel, or patient. Intention-to-treat analysis was used for all participants.

A total of 167 consecutive patients were evaluated for enrollment. From this total, 65 patients did not meet inclu- sion criteria, and 2 patients (1 male and 1 female) declined to participate; thus, 100 patients were ultimately enrolled (Figure 1). After agreeing to enroll, patients were random- ized to either the intervention or control group (n ¼ 50 patients each), with concealment of the allocation process. The randomization schedule was generated in blocks of 10 numbers (Research Randomizer; http://www.randomizer. org). One patient in the control group was lost to follow-up.

Participants received 1 of 2 regimens for pain manage- ment for a period of 6 days after hospital discharge. Patients in the intervention (blister pack) group received a novel blister pack of nonopioid analgesics containing 2 acetaminophen caplets 325 mg, celecoxib 100 mg, and preg- abalin 50 mg to be taken as scheduled doses 4 times a day for 6 days (Figure 2). This group was also given oxycodone 5 mg (40 tablets) to be taken every 4 hours (1-2 tablets) as needed for pain not controlled by the nonopioid analgesics.

Patients in the control group were instructed to use ibu- profen up to 800 mg every 8 hours as needed for pain control. In addition, patients received combined oxycodone 5 mg/acetaminophen 325 mg (40 tablets) to be taken as needed for pain every 4 hours (1-2 tablets). Patients in the control group were also allowed to use plain acetaminophen and instructed not to exceed 650 mg every 6 hours.

One hour before surgery, all participants received standardized oral multimodal analgesics consisting of acetaminophen 975 mg, celecoxib 400 mg, and pregabalin 150 mg. All patients with a known history of postoperative nausea and vomiting or motion sickness were treated 1 hour before surgery with a transdermal scopolamine patch (1.5 mg) that was left in place for 72 hours after application. Patients in both groups were provided with equipment for cold-pad knee circulation therapy at home after discharge from the postanesthesia care unit (PACU).

Anesthesia was induced with intravenous propofol 1.5 mg/kg and maintained using propofol 0.1 mg/kg/min and remifentanil 0.2 mg/kg/min. Intravenous fentanyl was given at the discretion of the anesthesiologist. Both groups received intravenous ondansetron 4 mg and dexametha- sone 0.1 mg/kg for nausea prophylaxis.

In the PACU, both groups received an ultrasound-guided ACB performed at the level of the distal third of the femur using a simplified ACB technique.27 Injectate for the ACB consisted of a 30-mL volume of preservative-free 0.5%

*Address correspondence to Jeffrey D. Swenson, MD, Department of Anesthesiology, University of Utah, Salt Lake City, UT 84132, USA (email: [email protected]).

†Department of Anesthesiology, University of Utah, Salt Lake City, Utah, USA. ‡Department of Pharmacy, University of Utah, Salt Lake City, Utah, USA. §Department of Orthopedic Surgery, University of Utah, Salt Lake City, Utah, USA. Final revision submitted August 5, 2022; accepted September 13, 2022. One or more of the authors has declared the following potential conflict of interest or source of funding: C.L.S. has received consulting fees from Smith &

Nephew, Wright Medical, and Zimmer Biomet; royalties from Limacorporate and Wright Medical; and hospitality payments from Lima USA. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto.

Ethical approval for this study was obtained from the University of Utah (reference No. 00121505).

2 Swenson et al The Orthopaedic Journal of Sports Medicine

bupivacaine with epinephrine 5 mg/mL. Patients received intravenous fentanyl at the discretion of the PACU nurse to achieve a level of analgesia that was acceptable to the patient while at rest.

Before discharge, patients received pain medications and instructions according to their assigned treatment group. Patients in the intervention group were given a blister pack (Figure 1) for scheduled doses of nonopioid analgesics. In addition, patients receive a prescription for oxycodone 5 mg tablets with instructions to take 1 to 2 by mouth every 4 hours as needed for pain.

Patients in the control group were instructed to take ibuprofen up to 800 mg every 8 hours as needed for pain. In addition, patients received a prescription for combined oxycodone 5 mg/acetaminophen 325 mg, 1 to 2 tablets every 4 hours as needed for pain. Patients were allowed to take plain acetaminophen; however, the total acetaminophen dose was limited to 650 mg every 6 hours. All patients had cell telephone access to the anesthesiologist and the option of an additional ACB within 48 hours of surgery.

A research assistant contacted each patient daily by tele- phone for 6 days after surgery to document pain scores, opioid requirements, and opioid-related adverse effects. Specifically, patients were asked to quantify their oxyco- done tablet consumption, average pain at rest, nausea, and itching on an 11-point verbal scale (from 0 to 10). These scores were recorded during each 12-hour period for 6 consec- utive postoperative days.

At the end of the study period, each patient was asked to empty the contents of their opioid medication bottle and

photograph all remaining pills with their cellular tele- phone. This photograph was sent via a text message to the research assistant to verify opioid use.

Statistical Methods

The sample size was based on an anticipated reduction in opioid consumption of 20% in the intervention group. With a chosen alpha of .05 and setting power of 80%, the sample size per group was 44 patients (http://ClinCalc.com). To account for possible attrition of patients, the planned study size was 100 patients with a 1:1 balance of intervention and control groups.

Demographic and anesthetic agent variables were dis- played as mean (±SD) or count (%). Covariate balance between the intervention and control groups after random- ization and before intervention was done by standardized mean difference (SMD). The primary outcome measure was pain reported twice daily for 6 days. The planned secondary outcomes were nausea and itching, also reported twice daily for 6 days. A post hoc secondary outcome was daily oxycodone use (number of tablets) for 6 days. The 11-point verbal scale scores and the count of oxycodone tablets were analyzed as ordinal variables.

Cumulative patient scores for pain, nausea, itching, and tablet use for the 6 days were compared between groups by Wilcoxon rank-sum test with estimation of the median of the difference between intervention and control samples. The 6 days of measurements represent longitudinal data. To avoid assumptions about the probability distribution of

167 ACLR patients evaluated Excluded (n = 67)

Did not meet inclusion criteria (n = 65) Declined to participate (n = 2)

Analyzed (n = 50) Excluded from analysis (n = 0)

Lost to follow-up (n = 0) Discontinued intervention (n = 0)

Allocated to intervention (n = 50) (28 autograft / 22 allograft)

Received intervention treatment (n = 50)

Lost to follow-up (n = 1) Discontinued intervention (n = 0)

Allocated to control (n = 50) (26 autograft / 24 allograft)

Received control treatment (n = 50)

Allocation

Analysis Analyzed (n = 49) Excluded from analysis (n = 0)

Follow-Up

Enrollment

Randomized (N = 100) 54 autograft / 46 allograft

Figure 1. Patient flowchart from enrollment and randomization to allocation, follow-up, and analysis. In total, 65 patients did not meet inclusion criteria because of age or weight (n ¼ 26), planned patellar tendon graft (n ¼ 28), or recent opioid use (n ¼ 11). Note that only 2 patients declined to participate in the trial. A single patient was lost to follow-up after ambulatory surgery. ACLR, anterior cruciate ligament reconstruction.

The Orthopaedic Journal of Sports Medicine Scheduled Dosing of 3 Nonopioid Analgesics After ACLR 3

the ordinal outcomes, robust rank-base analysis of variance methods was used to compare intervention and control samples with interaction by postoperative day.20 Also, pair- wise comparison for each 12-hour or 24-hour period was estimated by Wilcoxon nonparametric tests, with a false discovery rate adjustment of the P values using the Benjamini-Yekutieli procedure.

Tolerance intervals are estimated from a sample and provide limits that at least a certain proportion of a popula- tion falls within a given confidence interval.29 In addition to comparing the cumulative opioid requirements for patients in the control and intervention groups, analysis was per- formed to determine the upper tolerance limit to provide sufficient oxycodone tablets without requiring a refill (the opioid requirements) in 90% or 95% of control and interven- tion patients, respectively.

All analyses were performed using the R software lan- guage (Version 4.1.0) and the R packages nparLD (Version 2.1) and tolerance (Version 2.0.0). No data were imputed for the control patient who was lost to follow-up. The null hypothesis was rejected for P < .05; 95% CIs were obtained. Some statistics were rounded.

RESULTS

The participant data and anesthetic agents for all 100 par- ticipants are shown in Table 1. The distribution of demo- graphic covariates had SMD values exceeding 0.1; the magnitude of differences was not considered clinically rel- evant. The ratios of semitendinosus autograft/allograft were 28/22 for the intervention and 26/24 for the control groups. There were no additional unanticipated procedures performed in either group.

Three patients in the intervention group and 5 patients in the control group requested and were administered a repeat ACB to reduce pain on postoperative day 2. One patient in the control group refused ACB before discharge from the PACU. Two patients in the intervention group experienced dizziness, and in discussion with the providing physician, this was thought to be possibly related to prega- balin. One of these patients skipped a single dose of prega- balin on postoperative day 3 because of dizziness. The second patient discontinued pregabalin on postoperative day 4 and continued taking only celecoxib and acetamino- phen. A third patient in the intervention group reported a facial rash on postoperative day 2, which she attributed to celecoxib. She continued the trial uneventfully by substituting ibuprofen 600 mg for the celecoxib. No other adverse events or effects were observed during the trial. All outcomes were analyzed by intervention to treat for the 99 patients without any imputation of data for the missing control group patient.

As seen in Table 2, cumulative results for the 6 days, pain, nausea, itching, and oxycodone use were significantly lower in the intervention group. Most patients used no oxycodone in the intervention group. The sparsity of data prevented estimation of the difference of medians for nau- sea and itching.

The relative treatment effects for reducing opioid use and pain are displayed at 12- and 24-hour intervals in Figures 3 and 4. Use of oxycodone was less for the interven- tion group for each of the first 5 days. Pain differences by day were not significant. Data were too sparse for nausea

TABLE 1 Participant Characteristics and Anesthetic Drugsa

Variable Blister Pack

(n ¼ 50) Control (n ¼ 50) SMDb

Age, y 32 ± 11 37 ± 11 0.53 Male sex 13 (26) 18 (36) 0.22 Height, cm 169 ± 9 171 ± 8 0.29 Weight, kg 75 ± 13 80 ± 13 0.36 Body mass index 26 ± 6 27 ± 4 0.20 Scopolamine patch 19 (38) 19 (38) <0.001 Intraoperative fentanyl, mg 110 ± 45 110 ± 46 <0.001 PACU fentanyl, mg 93 ± 66 92 ± 77 0.01

aData are reported as mean ± SD or n (%). PACU, postanesthe- sia care unit; SMD, standardized mean difference.

bThe SMD checks covariate balance after randomization and before the intervention. SMD<0.1 is considered desirable for prog- nostically important covariates in a trial.

Figure 2. This blister pack drug-delivery system was provided to all patients in the intervention group. There are 6 rows with 4 compartments (morning, noon, evening, bedtime) in each row. Each compartment contains 1 pregabalin 50 mg cap- sule, 1 celecoxib 100 mg capsule, and 2 acetaminophen 325 mg caplets.

4 Swenson et al The Orthopaedic Journal of Sports Medicine

and itching to permit estimation of treatment effects across days.

DISCUSSION

In this prospective randomized clinical trial, the broad opioid-sparing effect produced by scheduled, simultaneous dosing of acetaminophen, celecoxib, and pregabalin reduced oxycodone requirements to zero for the majority of patients in the intervention group. The median (inter- quartile range) for total oxycodone tablets used by patients in the intervention group was 0 (0-2). Based on this study, we estimate that 90% of patients would require fewer than 8 oxycodone tablets during recovery. By contrast, 30 tablets are estimated to be required to achieve the same effect for patients in the control group. The reduction of opioid use observed in the study group was accompanied by signifi- cantly less overall pain.

After surgery, clinicians must balance the need to pro- vide adequate analgesia in some patients with the concern of overprescribing opioids in others. Without a clinically validated alternative, surgeons are understandably reluc- tant to decrease opioid prescriptions in the setting of mod- erate to severe postoperative pain. This tendency to “overprescribe” is evidenced by estimates that 42% to 71% of prescribed opioid tablets remain unused.2

The ability for providers to confidently prescribe fewer opioids is paramount since the quantity received for a patient’s initial prescription is a major predictor of chronic opioid use.25,26 However, most existing “opioid-free” proto- cols simply restrict or eliminate access to opioids during surgical recovery while providing a variety of nonopioid alternatives.5,12,15,17,23 Thus, an important aspect of our trial was to provide nonopioid alternatives for patients as well as unrestricted access to opioids.

In this study, a prefilled blister pack system (Figure 1) was used to facilitate medication compliance and achieve simultaneous actions of pregabalin, acetaminophen, and celecoxib. This simplified packaging provided all 3 medica- tions in 1 compartment to be taken at 6-hour intervals. Since the half-lives of celecoxib7 and pregabalin3 vary con- siderably from that of acetaminophen,10 their interval doses were adjusted accordingly. This novel form of drug delivery has important implications since each of these drugs has a unique opioid-sparing quality; however, their

simultaneous actions are rarely reported in an ambulatory setting.17

The analgesic regimen for patients in the control group was chosen to reflect current best practice protocols for pain control after ambulatory surgery.13 These protocols utilize peripheral nerve blocks, acetaminophen, and NSAIDs to optimize analgesia and minimize opioid requirements. Despite this extensive regimen, opioid requirements in the control group were significantly higher and more variable than for patients in the study group.

The prefilled medication blister pack featured in this trial (Figure 1) provided simultaneous effects of 3 analge- sics with unique mechanisms of action. A secondary out- come measure for this study was opioid use after ambulatory center discharge. Existing calculations for “opioid or morphine equivalents” represent the best esti- mates available but are imperfect.19 To avoid this potential inaccuracy, a single opioid analgesic (oxycodone) was used for all patients after hospital discharge.

The nonopioid medications used for this trial are well tolerated after oral administration with minimal adverse effects. Each drug provides onset of analgesia within 30 to 40 minutes of oral administration. Finally, they are avail- able in a cost-effective generic formulation. Techniques described for hospitalized patients such as parenteral keta- mine, lidocaine infusions, and dexmedetomidine are not suitable for use after hospital discharge.8

Acetaminophen is an important component of multi- modal analgesia with a mechanism of action that is unique from that of NSAIDs.10 Simultaneous administration of acetaminophen and NSAIDs produces improved analgesia and greater reductions in opioid requirements than either drug used in isolation.21

Celecoxib was chosen for this protocol because its selec- tive COX-2 activity preserves platelet function and mini- mizes gastrointestinal side effects in cases requiring repeated dosing.7 A 400 mg dose of celecoxib has been shown in earlier studies to provide significant reduction in pain and postoperative opioid requirements.24 Although it is commonly avoided in patients with an allergy to sul- fonamide antimicrobials, available data do not support cross-reactivity between sulfonamide antimicrobials and other sulfonamide medications such as celecoxib.14

Pregabalin was included as the third component of multimodal analgesia for the study group. Gabapentinoids are known to reduce opioid requirements as well as

TABLE 2 Cumulative (6-day total) Pain, Nausea, Itching, and Oxycodone Use VRS Scoresa

VRS Score (0-10) Blister Pack (n ¼ 50) Control (n ¼ 49)b Difference of Medians (95% CI) P

Pain 28 (14 to 35) 35 (28 to 41) –7 (–13 to –2) .009 Nausea 0 (0 to 0) 0 (0 to 6) NAc .006 Itching 0 (0 to 0) 0 (0 to 4) NAc < .001 Oxycodone use, 5-mg tablets 0 (0 to 2) 8 (1.25 to 16) –7 (–12 to –4) < .001

aResults are reported as median (interquartile range) unless otherwise indicated. Boldface P values indicate a statistically significant difference between study groups (P < .05). NA, not available; VRS, verbal rating scale.

bOne control patient was lost to follow-up. cThe sparseness of data for nausea and itching prevented estimation of the difference of medians.

The Orthopaedic Journal of Sports Medicine Scheduled Dosing of 3 Nonopioid Analgesics After ACLR 5

opioid-related side effects after surgery.16,28 Although both gabapentin and pregabalin have been used for acute pain management, pregabalin provides more predictable plasma concentrations and significantly faster onset of analgesia after oral administration.3 Side effects and adverse events associated with pregabalin are rare. In a recent meta- analysis of 281 clinical trials, serious adverse events such respiratory failure, delirium, falls, and ataxia did not significantly increase with the use of gabapentinoids.28

An important consideration when prescribing gabapen- tinoids is the potential for addiction or abuse. Recent reviews of pregabalin suggest that the risk of abuse in patients without a previous history of substance abuse dis- order is very low.11 The increased dopamine in the meso- limbic reward system produced by other drugs of abuse is not observed with pregabalin.4 However, for patients with

a history of substance abuse, gabapentinoids should be prescribed with caution and careful monitoring.

Respiratory depression is the primary cause of mortal- ity associated with opioid analgesics.6 As such, the ven- tilatory effects produced by pregabalin alone and in combination with opioids are critical to define. In volun- teers receiving pregabalin (150 mg) alone, there were no significant changes in minute ventilation, respiratory rate, or end-tidal CO2 compared with placebo.18 For volunteers receiving target-controlled infusions of remi- fentanil, the addition of pregabalin did not alter minute ventilation or respiratory rate but did cause a modest increase in end-tidal CO2 (6 mm Hg) compared with remifentanil alone.18

An important aspect of this study is the equitable treat- ment of pain for patients in the control group. Every

Figure 3. The counts of oxycodone tablet usage for each postoperative day are displayed by box plots. Each box goes from the 25th to the 75th percentile (interquartile range [IQR]) with a line indicating the median of the data. The whiskers start from the edge of the box and extend to the farthest data point that is within 1.5 times the upper bound of the IQR. The dots are the outlier values above the whiskers. No boxes are visible for the blister pack group, as the median, IQR, and whiskers were uniformly zero on all days. For oxycodone use, there was a difference (F(1, Inf)¼ 50; P< .001), a decrease over the 6 days (F(3.7, Inf)¼ 32; P< .001), and an interaction effect across days (F(3.7, Inf) ¼ 14; P < .001) favoring the blister pack group. Benjamini-Yekutieli–adjusted P values for pairwise comparisons demonstrated that the oxycodone count for the blister pack group was less than that for the control group for days 1 to 5.

6 Swenson et al The Orthopaedic Journal of Sports Medicine

consideration was made to ensure that pain control for the control group reflected existing best practice. To that end, patients in the control group received the same preopera- tive multimodal analgesics as those in the study group. Likewise, intraoperative anesthetics and postoperative nerve blocks were standardized between the 2 groups. Both groups received NSAIDs, oxycodone, and acetaminophen after hospital discharge.

For ethical reasons, a placebo-filled blister pack was not used, as this would not have permitted use of NSAIDs in patients in the control group. Oxycodone was combined with acetaminophen in patients in the control group to ensure that they benefited from the increased analgesia produced by combined acetaminophen and oxycodone com- pared with plain oxycodone.9 It should be noted, however, that patients in the control group were not prohibited from taking plain acetaminophen.

An important limitation of this trial is the inability to discern the true effects of medication delivery (blister pack vs no blister pack) and medications received (pregabalin vs no pregabalin). This effect could only be measured by study- ing these 2 interventions separately. It should also be noted that this blister pack system has been studied in a single procedure and the results should not be generalized with- out further clinical investigation. Similarly, this dosing reg- imen was applied to patients with a fixed range of weights and ages. There remains the opportunity to optimize dose response based on age and body mass.

A potential criticism of the enrollment process is that the study design may have discouraged patients who prefer opioid analgesia. This could cause a sampling bias leading only patients motivated to use less opioid to participate. However, only 2 eligible patients declined to participate after learning the objectives of this trial.

Figure 4. The verbal pain scores for each postoperative day are displayed by box plots. Each box goes from the 25th to the 75th percentile (interquartile range [IQR]), with a line indicating the median of the data. The whiskers start from the edge of the box and extend to the farthest data point that is within 1.5 times the upper bound of the IQR. The dots are the outlier values above the whiskers. There was a group difference (F(1, Inf) ¼ 7.5; P ¼ .006) and a decrease over the 6 days (F(5.0, Inf) ¼ 42; P < .001) favoring the blister pack group, but no significant interaction effect across days (F(5.0, Inf) ¼ 1.4; P ¼ .2). There were no significant pairwise differences during the 6 days according to Benjamini-Yekutieli–adjusted P values.

The Orthopaedic Journal of Sports Medicine Scheduled Dosing of 3 Nonopioid Analgesics After ACLR 7

CONCLUSION

The blister pack system is novel as it provides scheduled, simultaneous action of 3 separate nonopioid analgesics. Its use is associated with reductions in both pain and opioid use after ACLR. The median (interquartile range) for total oxycodone tablets used by patients in the study group was 0 (0-2). Based on the results for the study group, it is pre- dicted that a population of similar patients will have a 90% upper tolerance limit for opioid use during recovery of 8 oxycodone (5 mg) tablets. These findings allow practi- tioners to confidently prescribe lower amounts of opioid without concerns of undertreating pain when using this protocol. Further work on dosage of components within the blister pack should be performed to optimize the efficacy of nonopioid management of postoperative pain.

REFERENCES

1. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and

side effects. Pain Physician. 2008;11(2)(suppl):S105-S120.

2. Bicket MC, Long JJ, Pronovost PJ, Alexander GC, Wu CL. Prescrip-

tion opioid analgesics commonly unused after surgery: a systematic

review. JAMA Surg. 2017;152(11):1066-1071.

3. Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P.

A comparison of the pharmacokinetics and pharmacodynamics of

pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):

661-669.

4. Bonnet U, Scherbaum N. How addictive are gabapentin and prega-

balin? A systematic review. Eur Neuropsychopharmacol. 2017;27(12):

1185-1215.

5. Daniels SD, Garvey KD, Collins JE, Matzkin EG. Patient satisfaction

with nonopioid pain management following arthroscopic partial

meniscectomy and/or chondroplasty. Arthroscopy. 2019;35(6):

1641-1647.

6. Dolinak D. Opioid toxicity. Acad Forensic Pathol. 2017;7(1):19-35.

7. Frampton JE, Keating GM. Celecoxib: a review of its use in the man-

agement of arthritis and acute pain. Drugs. 2007;67(16):2433-2472.

8. Gabriel RA, Swisher MW, Sztain JF, Furnish TJ, Ilfeld BM, Said ET.

State of the art opioid-sparing strategies for post-operative pain in

adult surgical patients. Expert Opin Pharmacother. 2019;20(8):

949-961.

9. Gaskell H, Derry S, Moore RA, McQuay HJ. Single dose oral oxyco-

done and oxycodone plus paracetamol (acetaminophen) for acute

postoperative pain in adults. Cochrane Database Syst Rev. 2009;

2009(3):CD002763.

10. Ghanem CI, Pérez MJ, Manautou JE, Mottino AD. Acetaminophen

from liver to brain: new insights into drug pharmacological action and

toxicity. Pharmacol Res. 2016;109:119-131.

11. Hägg S, Jönsson AK, Ahlner J. Current evidence on abuse and mis-

use of gabapentinoids. Drug Saf. 2020;43(12):1235-1254.

12. Hajewski CJ, Westermann RW, Holte A, Shamrock A, Bollier M, Wolf

BR. Impact of a standardized multimodal analgesia protocol on opioid

prescriptions after common arthroscopic procedures. Orthop J

Sports Med. 2019;7(9):2325967119870753.

13. Joshi GP. Enhanced recovery pathways for ambulatory surgery. Curr

Opin Anaesthesiol. 2020;33(6):711-717.

14. Knowles S, Shapiro L, Shear NH. Should celecoxib be contraindi-

cated in patients who are allergic to sulfonamides? Revisiting the

meaning of “sulfa” allergy. Drug Saf. 2001;24(4):239-247.

15. Mark J, Argentieri DM, Gutierrez CA, et al. Ultrarestrictive opioid pre-

scription protocol for pain management after gynecologic and

abdominal surgery. JAMA Netw Open. 2018;1(8):e185452.

16. Mishriky BM, Waldron NH, Habib AS. Impact of pregabalin on acute and

persistent postoperative pain: a systematic review and meta-analysis.

Br J Anaesth. 2015;114(1):10-31.

17. Moutzouros V, Jildeh TR, Tramer JS, et al. Can we eliminate opioids

after anterior cruciate ligament reconstruction? A prospective, ran-

domized controlled trial. Am J Sports Med. 2021;49(14):3794-3801.

18. Myhre M, Diep LM, Stubhaug A. Pregabalin has analgesic, ventilatory,

and cognitive effects in combination with remifentanil. Anesthesiology.

2016;124(1):141-149.

19. Nielsen S, Degenhardt L, Hoban B, Gisev N. A synthesis of oral mor-

phine equivalents (OME) for opioid utilisation studies. Pharmacoepi-

demiol Drug Saf. 2016;25(6):733-737.

20. Noguchi K, Gel YR, Brunner E, Konietschke F. nparLD: an R software

package for the nonparametric analysis of longitudinal data in facto-

rial experiments. J Stat Softw. 2012;50(12):1-23.

21. Ong CK, Seymour RA, Lirk P, Merry AF. Combining paracetamol

(acetaminophen) with nonsteroidal antiinflammatory drugs: a qualita-

tive systematic review of analgesic efficacy for acute postoperative

pain. Anesth Analg. 2010;110(4):1170-1179.

22. Pantuzza LL, Ceccato MDGB, Silveira MR, Junqueira LMR, Reis

AMM. Association between medication regimen complexity and

pharmacotherapy adherence: a systematic review. Eur J Clin Phar-

macol. 2017;73(11):1475-1489.

23. Papoian V, Handy KG, Villano AM, et al. Randomized control trial of

opioid-versus nonopioid-based analgesia after thyroidectomy. Surgery.

2020;167(6):957-961.

24. Recart A, Issioui T, White PF, et al. The efficacy of celecoxib preme-

dication on postoperative pain and recovery times after ambulatory

surgery: a dose-ranging study. Anesth Analg. 2003;96(6):1631-1635.

25. Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription

episodes and likelihood of long-term opioid use—United States,

2006-2015. MMWR Morb Mortal Wkly Rep. 2017;66(10):265-269.

26. Shah A, Hayes CJ, Martin BC. Factors influencing long-term opioid

use among opioid naive patients: an examination of initial prescription

characteristics and pain etiologies. J Pain. 2017;18(11):1374-1383.

27. Swenson JD, Pollard JE, Peters CL, Anderson MB, Pace NL. Ran-

domized controlled trial of a simplified adductor canal block per-

formed for analgesia following total knee arthroplasty. Reg Anesth

Pain Med. 2019;44(3):348-353.

28. Verret M, Lauzier F, Zarychanski R, et al. Perioperative use of gaba-

pentinoids for the management of postoperative acute pain: a sys-

tematic review and meta-analysis. Anesthesiology. 2020;133(2):

265-279.

29. Young DS. Tolerance: an R package for estimating tolerance interval.

J Stat Softw. 2010;36(5):1-39.

8 Swenson et al The Orthopaedic Journal of Sports Medicine

<< /ASCII85EncodePages false /AllowTransparency false /AutoPositionEPSFiles true /AutoRotatePages /None /Binding /Left /CalGrayProfile (Gray Gamma 2.2) /CalRGBProfile (sRGB IEC61966-2.1) /CalCMYKProfile (U.S. Web Coated \050SWOP\051 v2) /sRGBProfile (sRGB IEC61966-2.1) /CannotEmbedFontPolicy /Warning /CompatibilityLevel 1.4 /CompressObjects /Off /CompressPages true /ConvertImagesToIndexed true /PassThroughJPEGImages false /CreateJobTicket false /DefaultRenderingIntent /Default /DetectBlends true /DetectCurves 0.1000 /ColorConversionStrategy /LeaveColorUnchanged /DoThumbnails false /EmbedAllFonts true /EmbedOpenType false /ParseICCProfilesInComments true /EmbedJobOptions true /DSCReportingLevel 0 /EmitDSCWarnings false /EndPage -1 /ImageMemory 1048576 /LockDistillerParams true /MaxSubsetPct 100 /Optimize true /OPM 1 /ParseDSCComments true /ParseDSCCommentsForDocInfo true /PreserveCopyPage true /PreserveDICMYKValues true /PreserveEPSInfo true /PreserveFlatness false /PreserveHalftoneInfo false /PreserveOPIComments false /PreserveOverprintSettings true /StartPage 1 /SubsetFonts true /TransferFunctionInfo /Apply /UCRandBGInfo /Remove /UsePrologue false /ColorSettingsFile () /AlwaysEmbed [ true ] /NeverEmbed [ true ] /AntiAliasColorImages false /CropColorImages false /ColorImageMinResolution 266 /ColorImageMinResolutionPolicy /OK /DownsampleColorImages true /ColorImageDownsampleType /Average /ColorImageResolution 175 /ColorImageDepth -1 /ColorImageMinDownsampleDepth 1 /ColorImageDownsampleThreshold 1.50286 /EncodeColorImages true /ColorImageFilter /DCTEncode /AutoFilterColorImages true /ColorImageAutoFilterStrategy /JPEG /ColorACSImageDict << /QFactor 0.40 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /ColorImageDict << /QFactor 0.76 /HSamples [2 1 1 2] /VSamples [2 1 1 2] >> /JPEG2000ColorACSImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /JPEG2000ColorImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /AntiAliasGrayImages false /CropGrayImages false /GrayImageMinResolution 266 /GrayImageMinResolutionPolicy /OK /DownsampleGrayImages true /GrayImageDownsampleType /Average /GrayImageResolution 175 /GrayImageDepth -1 /GrayImageMinDownsampleDepth 2 /GrayImageDownsampleThreshold 1.50286 /EncodeGrayImages true /GrayImageFilter /DCTEncode /AutoFilterGrayImages true /GrayImageAutoFilterStrategy /JPEG /GrayACSImageDict << /QFactor 0.40 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /GrayImageDict << /QFactor 0.76 /HSamples [2 1 1 2] /VSamples [2 1 1 2] >> /JPEG2000GrayACSImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /JPEG2000GrayImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /AntiAliasMonoImages false /CropMonoImages false /MonoImageMinResolution 900 /MonoImageMinResolutionPolicy /OK /DownsampleMonoImages true /MonoImageDownsampleType /Average /MonoImageResolution 175 /MonoImageDepth -1 /MonoImageDownsampleThreshold 1.50286 /EncodeMonoImages true /MonoImageFilter /CCITTFaxEncode /MonoImageDict << /K -1 >> /AllowPSXObjects false /CheckCompliance [ /None ] /PDFX1aCheck false /PDFX3Check false /PDFXCompliantPDFOnly false /PDFXNoTrimBoxError true /PDFXTrimBoxToMediaBoxOffset [ 0.00000 0.00000 0.00000 0.00000 ] /PDFXSetBleedBoxToMediaBox false /PDFXBleedBoxToTrimBoxOffset [ 0.00000 0.00000 0.00000 0.00000 ] /PDFXOutputIntentProfile (U.S. Web Coated \050SWOP\051 v2) /PDFXOutputConditionIdentifier (CGATS TR 001) /PDFXOutputCondition () /PDFXRegistryName (http://www.color.org) /PDFXTrapped /Unknown /CreateJDFFile false /Description << /ENU <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> >> /Namespace [ (Adobe) (Common) (1.0) ] /OtherNamespaces [ << /AsReaderSpreads false /CropImagesToFrames true /ErrorControl /WarnAndContinue /FlattenerIgnoreSpreadOverrides false /IncludeGuidesGrids false /IncludeNonPrinting false /IncludeSlug false /Namespace [ (Adobe) (InDesign) (4.0) ] /OmitPlacedBitmaps false /OmitPlacedEPS false /OmitPlacedPDF false /SimulateOverprint /Legacy >> << /AllowImageBreaks true /AllowTableBreaks true /ExpandPage false /HonorBaseURL true /HonorRolloverEffect false /IgnoreHTMLPageBreaks false /IncludeHeaderFooter false /MarginOffset [ 0 0 0 0 ] /MetadataAuthor () /MetadataKeywords () /MetadataSubject () /MetadataTitle () /MetricPageSize [ 0 0 ] /MetricUnit /inch /MobileCompatible 0 /Namespace [ (Adobe) (GoLive) (8.0) ] /OpenZoomToHTMLFontSize false /PageOrientation /Portrait /RemoveBackground false /ShrinkContent true /TreatColorsAs /MainMonitorColors /UseEmbeddedProfiles false /UseHTMLTitleAsMetadata true >> << /AddBleedMarks false /AddColorBars false /AddCropMarks false /AddPageInfo false /AddRegMarks false /BleedOffset [ 9 9 9 9 ] /ConvertColors /ConvertToRGB /DestinationProfileName (sRGB IEC61966-2.1) /DestinationProfileSelector /UseName /Downsample16BitImages true /FlattenerPreset << /ClipComplexRegions true /ConvertStrokesToOutlines false /ConvertTextToOutlines false /GradientResolution 300 /LineArtTextResolution 1200 /PresetName ([High Resolution]) /PresetSelector /HighResolution /RasterVectorBalance 1 >> /FormElements true /GenerateStructure false /IncludeBookmarks false /IncludeHyperlinks false /IncludeInteractive false /IncludeLayers false /IncludeProfiles true /MarksOffset 9 /MarksWeight 0.125000 /MultimediaHandling /UseObjectSettings /Namespace [ (Adobe) (CreativeSuite) (2.0) ] /PDFXOutputIntentProfileSelector /DocumentCMYK /PageMarksFile /RomanDefault /PreserveEditing true /UntaggedCMYKHandling /UseDocumentProfile /UntaggedRGBHandling /UseDocumentProfile /UseDocumentBleed false >> ] /SyntheticBoldness 1.000000 >> setdistillerparams << /HWResolution [288 288] /PageSize [612.000 792.000] >> setpagedevice